Glivec
Phase 3Gene therapy
Chong Kun Dang PharmaceuticalGlivec is one of 152 small molecule programs targeting Leukemia. It is currently in Phase 3.
4
Indications
13
Total Trials
1
Active Trials
151
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Tabloid
Akero TherapeuticsPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
AG-120
Institut de Recherches Internationales ServierPhase 3
Sapacitabine
CCyclacel Pharmaceuticals, Inc.
Phase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Phase 3
Glivec
Chong Kun Dang PharmaceuticalPhase 3
ALL-Trans Retinoid Acid
UUniversity of Ulm
Phase 3
Leukine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myeloid Leukemia2 trials
Carcinoma1 trial
Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct
Completed·—·Phase 2·NCT01153750·44 enrolled
Monotherapy1 trial
7 more indications
Gastrointestinal Stromal Tumor1 trial
Leukaemia1 trial
Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glivec. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details